随着对乳腺或卵巢癌患者的遗传学测试成为医疗保健的一部分，对遗传学测试的需求不断增加，患者对可靠遗传学信息易于获得的需求也在增加。因此，我们开发了一款能够进行关于遗传BRCA基因测试的人工智能对话的聊天机器人应用程序（Rosa）。在将这项新的信息服务应用于日常临床实践之前，我们想探讨聊天机器人使用的两个方面：在患有遗传性癌症风险的健康患者中，聊天机器人技术的实用性和信任感，以及与聊天机器人进行有关遗传性癌症敏感信息的互动对患者的影响。总体上，我们邀请了175名患有遗传性乳腺和卵巢癌风险的健康人群在遗传咨询前后测试聊天机器人Rosa。为了获得多样化的样本，参与者是在挪威所有癌症遗传诊所中招募的，并基于年龄、性别和有BRCA致病变异风险的选择。在同意接受个人访谈的61名（175中的34.9%）参与者中，一部分被选中（16/61，26%）通过视频进行了深度访谈，半结构化访谈内容涵盖了以下主题：可用性、感知有用性、对通过聊天机器人接收到的信息的信任程度、Rosa对用户的影响以及对将来在医疗保健中使用数字工具的想法。采用逐步演绎归纳的方法对文本进行了分析。总体发现是，参与者非常欢迎聊天机器人。他们很欣赏无论他们身在何处，都能够享受到24/7 不间断的服务，以及准备遗传咨询和之后重复和提问相关问题的可能性。由于Rosa由医疗保健专业人士创建，他们也认为自己收到的信息在医学上是准确的。与Google相比，Rosa被认为提供了具体可靠的答案。这些发现总结为三个概念：“随时随地”、“之外，而非取代”和“值得信赖和真实”。所有参与者（16/16）否认阅读有关遗传测试、遗传性乳腺和卵巢癌的Rosa后有因此而增加的担忧。我们的研究结果表明，遗传信息聊天机器人可以为具有遗传性乳腺和卵巢癌风险的患者提供易于获得的统一信息，无论其地理位置如何。质量有保证的信息在24/7 不间断的提供下，根据特定情况量身定制，对我们的参与者有一种安抚作用。在概念上保持一致，Rosa是准备和重复的工具；然而，没有参与者（0/16）支持Rosa可以取代遗传咨询，如果遗传性癌症得到确认的话。这说明聊天机器人可以成为适合的遗传咨询数字伴侣。 ©Elen Siglen, Hildegunn Høberg Vetti, Mirjam Augestad, Vidar M Steen, Åshild Lunde, Cathrine Bjorvatn. 原文发表于《医学互联网研究杂志》（https://www.jmir.org），2023年1月9日。

Genetic testing has become an integrated part of health care for patients with breast or ovarian cancer, and the increasing demand for genetic testing is accompanied by an increasing need for easy access to reliable genetic information for patients. Therefore, we developed a chatbot app (Rosa) that is able to perform humanlike digital conversations about genetic BRCA testing.Before implementing this new information service in daily clinical practice, we wanted to explore 2 aspects of chatbot use: the perceived utility and trust in chatbot technology among healthy patients at risk of hereditary cancer and how interaction with a chatbot regarding sensitive information about hereditary cancer influences patients.Overall, 175 healthy individuals at risk of hereditary breast and ovarian cancer were invited to test the chatbot, Rosa, before and after genetic counseling. To secure a varied sample, participants were recruited from all cancer genetic clinics in Norway, and the selection was based on age, gender, and risk of having a BRCA pathogenic variant. Among the 34.9% (61/175) of participants who consented for individual interview, a selected subgroup (16/61, 26%) shared their experience through in-depth interviews via video. The semistructured interviews covered the following topics: usability, perceived usefulness, trust in the information received via the chatbot, how Rosa influenced the user, and thoughts about future use of digital tools in health care. The transcripts were analyzed using the stepwise-deductive inductive approach.The overall finding was that the chatbot was very welcomed by the participants. They appreciated the 24/7 availability wherever they were and the possibility to use it to prepare for genetic counseling and to repeat and ask questions about what had been said afterward. As Rosa was created by health care professionals, they also valued the information they received as being medically correct. Rosa was referred to as being better than Google because it provided specific and reliable answers to their questions. The findings were summed up in 3 concepts: "Anytime, anywhere"; "In addition, not instead"; and "Trustworthy and true." All participants (16/16) denied increased worry after reading about genetic testing and hereditary breast and ovarian cancer in Rosa.Our results indicate that a genetic information chatbot has the potential to contribute to easy access to uniform information for patients at risk of hereditary breast and ovarian cancer, regardless of geographical location. The 24/7 availability of quality-assured information, tailored to the specific situation, had a reassuring effect on our participants. It was consistent across concepts that Rosa was a tool for preparation and repetition; however, none of the participants (0/16) supported that Rosa could replace genetic counseling if hereditary cancer was confirmed. This indicates that a chatbot can be a well-suited digital companion to genetic counseling.©Elen Siglen, Hildegunn Høberg Vetti, Mirjam Augestad, Vidar M Steen, Åshild Lunde, Cathrine Bjorvatn. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 01.09.2023.